Clinical trials: ARDS (Moderate or Severe)
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University